Neuburgh Advisers LLC raised its position in shares of Petmed Express Inc (NASDAQ:PETS) by 20.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,732 shares of the company’s stock after purchasing an additional 1,156 shares during the quarter. Neuburgh Advisers LLC’s holdings in Petmed Express were worth $105,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. Texas Permanent School Fund grew its stake in Petmed Express by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 14,037 shares of the company’s stock valued at $320,000 after purchasing an additional 508 shares during the last quarter. Carillon Tower Advisers Inc. grew its stake in Petmed Express by 0.8% during the 1st quarter. Carillon Tower Advisers Inc. now owns 78,764 shares of the company’s stock valued at $1,794,000 after purchasing an additional 600 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Petmed Express by 0.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 114,919 shares of the company’s stock valued at $1,801,000 after purchasing an additional 767 shares during the last quarter. Riverhead Capital Management LLC grew its stake in Petmed Express by 19.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,917 shares of the company’s stock valued at $77,000 after purchasing an additional 800 shares during the last quarter. Finally, Freestone Capital Holdings LLC purchased a new stake in Petmed Express during the 1st quarter valued at about $22,780,000. Institutional investors and hedge funds own 97.46% of the company’s stock.
A number of analysts have recently commented on the company. BidaskClub upgraded Petmed Express from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Craig Hallum downgraded Petmed Express from a “buy” rating to a “hold” rating and set a $15.00 target price on the stock. in a research note on Friday, August 16th.
Petmed Express (NASDAQ:PETS) last issued its earnings results on Monday, July 22nd. The company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.16). The company had revenue of $79.99 million during the quarter, compared to analysts’ expectations of $85.83 million. Petmed Express had a return on equity of 23.42% and a net margin of 11.05%. The firm’s quarterly revenue was down 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.62 EPS.
About Petmed Express
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Recommended Story: How is diluted EPS different from basic EPS?
Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Petmed Express Inc (NASDAQ:PETS).
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.